Detail akcie Keros Therap Rg online

Business Summary: Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing novel therapeutics to treat a range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (TGF-B), family of proteins. Its lead product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, and in patients with myelofibrosis. Its product candidate, KER-012, is being developed for the treatment of pulmonary arterial hypertension, or PAH, and for the treatment of cardiovascular disorders. Its product candidate, KER-065, is being developed for the treatment of obesity and for the treatment of neuromuscular diseases. KER-050 is designed to raise red blood cell and platelet production by inhibiting the signaling of a subset of the TGF-B family of proteins to promote hematopoiesis.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Keros Therapeutics Inc revenues increased from $508K to $243.7M. Net income totaled $110.5M vs. loss of $141.3M. Revenues reflect PHARMACEUTICAL PREPARATIONS segment increase from $388K to $243.7M. Net Income reflects PHARMACEUTICAL PREPARATIONS segment income totaling $96.8M vs. loss of $58.7M. Basic Earnings per Share excluding Extraordinary Items increased from -$3.87 to $2.73.